Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ABBV NASDAQ:ALEC NASDAQ:AMLX NASDAQ:ATHA NASDAQ:COYA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABBVAbbVie$195.17+3.3%$188.33$163.81▼$218.66$333.89B0.55.44 million shs8.08 million shsALECAlector$1.45-2.7%$1.52$0.87▼$6.37$148.99M0.86439,584 shs737,122 shsAMLXAmylyx Pharmaceuticals$7.72-3.9%$6.50$1.76▼$8.72$715.80M-0.491.45 million shs1.84 million shsATHAAthira Pharma$0.37-2.6%$0.35$0.22▼$3.67$14.84M3276,295 shs348,705 shsCOYACoya Therapeutics$6.09+2.4%$5.86$4.65▼$10.24$99.51M0.2683,647 shs39,841 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABBVAbbVie+3.25%+2.60%+2.30%-1.74%+5.32%ALECAlector-2.68%-17.61%-3.33%+11.54%-75.83%AMLXAmylyx Pharmaceuticals-3.86%-5.28%+17.50%+45.11%+274.76%ATHAAthira Pharma-2.58%-19.17%+22.95%+28.54%-88.39%COYACoya Therapeutics+2.35%-8.70%+5.36%-4.40%-11.22%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABBVAbbVie4.573 of 5 stars2.44.03.33.93.91.71.3ALECAlector4.0287 of 5 stars3.13.00.04.53.02.50.0AMLXAmylyx Pharmaceuticals2.5111 of 5 stars4.51.00.00.00.02.50.6ATHAAthira Pharma3.2286 of 5 stars3.05.00.00.01.13.31.3COYACoya Therapeutics1.9676 of 5 stars3.53.00.00.02.00.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABBVAbbVie 2.81Moderate Buy$212.819.04% UpsideALECAlector 2.29Hold$4.17187.36% UpsideAMLXAmylyx Pharmaceuticals 3.00Buy$11.7552.20% UpsideATHAAthira Pharma 2.00Hold$11.252,938.90% UpsideCOYACoya Therapeutics 3.00Buy$16.50170.94% UpsideCurrent Analyst Ratings BreakdownLatest AMLX, ALEC, ABBV, ATHA, and COYA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/1/2025ABBVAbbVieMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$250.00 ➝ $255.008/1/2025ABBVAbbVieGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$216.00 ➝ $227.008/1/2025ABBVAbbVieRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$227.00 ➝ $236.007/28/2025ALECAlectorMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Outperform$2.50 ➝ $3.507/24/2025COYACoya TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.007/10/2025AMLXAmylyx PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$10.007/9/2025COYACoya TherapeuticsLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$16.007/1/2025COYACoya TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.006/24/2025AMLXAmylyx PharmaceuticalsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageHold6/24/2025AMLXAmylyx PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold6/24/2025AMLXAmylyx PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$17.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABBVAbbVie$56.33B6.12$15.42 per share12.66$1.90 per share102.72ALECAlector$100.56M1.44N/AN/A$1.29 per share1.12AMLXAmylyx Pharmaceuticals-$1.27M-541.01N/AN/A$2.40 per share3.22ATHAAthira PharmaN/AN/AN/AN/A$1.16 per shareN/ACOYACoya Therapeutics$3.69M27.64N/AN/A$2.37 per share2.57Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABBVAbbVie$4.28B$2.3592.9413.961.256.45%518.10%13.61%N/AALECAlector-$119.05M-$1.26N/AN/AN/A-139.74%-100.58%-25.15%8/6/2025 (Estimated)AMLXAmylyx Pharmaceuticals-$301.74M-$3.11N/AN/AN/AN/A-77.21%-63.84%8/7/2025 (Confirmed)ATHAAthira Pharma-$96.94M-$2.07N/AN/AN/AN/A-142.99%-106.40%8/7/2025 (Estimated)COYACoya Therapeutics-$14.88M-$1.07N/AN/AN/AN/A-48.88%-43.32%8/11/2025 (Estimated)Latest AMLX, ALEC, ABBV, ATHA, and COYA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025COYACoya Therapeutics-$0.22N/AN/AN/AN/AN/A8/7/2025Q2 2025AMLXAmylyx Pharmaceuticals-$0.43N/AN/AN/AN/AN/A8/7/2025Q2 2025ATHAAthira Pharma-$0.18N/AN/AN/AN/AN/A8/6/2025Q2 2025ALECAlector-$0.45N/AN/AN/A$2.76 millionN/A7/31/2025Q2 2025ABBVAbbVie$3.24$2.97-$0.27$0.52$14.93 billion$15.42 billion5/13/2025Q1 2025COYACoya Therapeutics-$0.44-$0.44N/A-$0.44$2.63 million$257.88 million5/9/2025Q1 2025ATHAAthira Pharma-$0.20-$0.23-$0.03-$0.23N/AN/A5/8/2025Q1 2025AMLXAmylyx Pharmaceuticals-$0.45-$0.42+$0.03-$0.42N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABBVAbbVie$6.563.36%N/A279.15%53 YearsALECAlectorN/AN/AN/AN/AN/AAMLXAmylyx Pharmaceuticals$1.0213.16%N/AN/A N/AATHAAthira PharmaN/AN/AN/AN/AN/ACOYACoya TherapeuticsN/AN/AN/AN/AN/ALatest AMLX, ALEC, ABBV, ATHA, and COYA DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date6/20/2025ABBVAbbViequarterly$1.643.54%7/15/20257/15/20258/15/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABBVAbbVie44.140.760.64ALECAlector0.103.343.34AMLXAmylyx PharmaceuticalsN/A12.0512.05ATHAAthira PharmaN/A7.267.26COYACoya TherapeuticsN/A8.848.84Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABBVAbbVie70.23%ALECAlector85.83%AMLXAmylyx Pharmaceuticals95.84%ATHAAthira Pharma57.12%COYACoya Therapeutics39.75%Insider OwnershipCompanyInsider OwnershipABBVAbbVie0.25%ALECAlector9.10%AMLXAmylyx Pharmaceuticals11.70%ATHAAthira Pharma22.10%COYACoya Therapeutics12.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABBVAbbVie55,0001.77 billion1.76 billionOptionableALECAlector27099.99 million90.89 millionOptionableAMLXAmylyx Pharmaceuticals20089.14 million78.71 millionOptionableATHAAthira Pharma4039.04 million30.41 millionOptionableCOYACoya Therapeutics616.73 million14.72 millionNot OptionableAMLX, ALEC, ABBV, ATHA, and COYA HeadlinesRecent News About These CompaniesFDA misses IND deadline for Coya’s ALS asset, cites lack of resourcesJuly 30 at 2:20 PM | fiercebiotech.comFDauntless Investment Group LLC Acquires Shares of 167,378 Coya Therapeutics, Inc. (NASDAQ:COYA)July 29, 2025 | marketbeat.comCoya Therapeutics (NASDAQ:COYA) Earns "Buy" Rating from D. Boral CapitalJuly 27, 2025 | americanbankingnews.comCoya Therapeutics' (COYA) "Buy" Rating Reiterated at D. Boral CapitalJuly 25, 2025 | marketbeat.comCoya Therapeutics, Inc. (COYA) Surges 10.7%: Is This an Indication of Further Gains?July 25, 2025 | zacks.comCoya Therapeutics Announces Publication of Scientific Research Linking Inflammation and Oxidative Stress to the Progression of Parkinson’s DiseaseJuly 24, 2025 | joplinglobe.comJCoya Therapeutics to Participate in the BTIG Virtual Biotechnology Conference July 29 – 30, 2025July 22, 2025 | finance.yahoo.comCoya Therapeutics to Participate in the BTIG Virtual Biotechnology Conference July 29 – 30, 2025July 22, 2025 | businesswire.comLake Street Initiates Coverage of Coya Therapeutics (COYA) with Buy RecommendationJuly 10, 2025 | msn.comLake Street Capital Initiates Coverage on Coya Therapeutics (NASDAQ:COYA)July 9, 2025 | marketbeat.comALS Patients Petition FDA To Reconsider BrainStorm’s NurOwn, Pointing to Recent Survival DataJuly 8, 2025 | biospace.comBCoya Therapeutics resubmits IND application for ALS Phase 2 study to FDA - Investing.comJuly 2, 2025 | investing.comPositive Outlook for Coya Therapeutics, Inc. Driven by IND Resubmission and Promising Trial ResultsJuly 1, 2025 | tipranks.comAfter myriad failures, a new wave of ALS drugs approachesJune 25, 2025 | finance.yahoo.comCoya Therapeutics Inc News - MorningstarJune 24, 2025 | morningstar.comMCoya Therapeutics to Present at the iAccess Alpha Virtual Best Ideas Summer Conference on June 24 – 25, 2025June 18, 2025 | businesswire.comCoya Therapeutics: How Fair Value analysis predicted 40% downside in biotech stockJune 12, 2025 | uk.investing.comCoya Therapeutics secures patent for IL-2 liquid formulationJune 4, 2025 | uk.investing.comCoya Therapeutics First Quarter 2025 Earnings: Misses ExpectationsMay 20, 2025 | finance.yahoo.comCoya Therapeutics: Promising Developments and Strategic Partnerships Drive Buy RatingMay 19, 2025 | tipranks.comCoya Therapeutics to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor ConferenceMay 16, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military Spend3 Short Squeeze Candidates With Big Catalysts on the HorizonBy Dan Schmidt | July 25, 2025View 3 Short Squeeze Candidates With Big Catalysts on the HorizonHow a Government Loan Changes the Game for Plug PowerBy Jeffrey Neal Johnson | July 4, 2025View How a Government Loan Changes the Game for Plug PowerThese 3 Undervalued Stocks Could Surge as Value Rotation NearsBy Gabriel Osorio-Mazilli | July 14, 2025View These 3 Undervalued Stocks Could Surge as Value Rotation NearsAbbVie Stock Eyes Breakout as Pipeline and Profits GrowBy Chris Markoch | July 31, 2025View AbbVie Stock Eyes Breakout as Pipeline and Profits GrowAMLX, ALEC, ABBV, ATHA, and COYA Company DescriptionsAbbVie NYSE:ABBV$195.17 +6.15 (+3.25%) Closing price 08/1/2025 03:59 PM EasternExtended Trading$195.10 -0.07 (-0.04%) As of 08/1/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.Alector NASDAQ:ALEC$1.45 -0.04 (-2.68%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.44 0.00 (-0.34%) As of 08/1/2025 05:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.Amylyx Pharmaceuticals NASDAQ:AMLX$7.72 -0.31 (-3.86%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$7.56 -0.16 (-2.07%) As of 08/1/2025 06:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.Athira Pharma NASDAQ:ATHA$0.37 -0.01 (-2.58%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$0.36 -0.01 (-3.30%) As of 08/1/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.Coya Therapeutics NASDAQ:COYA$6.09 +0.14 (+2.35%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$6.06 -0.04 (-0.57%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Why Bloom Energy Stock Could Break to New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
